Neuronetics Inc Net Assets
Neuronetics Inc net assets. Based on the latest financial reports, Neuronetics Inc (STIM) has net assets worth $17.06 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($125.44 Million) and total liabilities ($108.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Neuronetics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.06 Million |
| % of Total Assets | 13.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | -69.19% |
| 10-Year Change | N/A |
| Growth Volatility | 93.07 |
Net Assets of Neuronetics Inc (2016–2025)
Net assets of Neuronetics Inc from 2016 to 2025. This chart illustrates how Neuronetics Inc's net assets have evolved over time, based on quarterly financial data. See Neuronetics Inc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Neuronetics Inc (2016–2025)
The table below shows the annual net assets of Neuronetics Inc from 2016 to 2025. For live market cap and overall valuation, see Neuronetics Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $26.24 Million | -17.48% |
| 2024-12-31 | $31.80 Million | -6.99% |
| 2023-12-31 | $34.19 Million | -40.08% |
| 2022-12-31 | $57.06 Million | -33.01% |
| 2021-12-31 | $85.17 Million | +234.11% |
| 2020-12-31 | $25.49 Million | -46.73% |
| 2019-12-31 | $47.85 Million | -32.64% |
| 2018-12-31 | $71.04 Million | +136.88% |
| 2017-12-31 | $-192.65 Million | -8.77% |
| 2016-12-31 | $-177.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neuronetics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27790000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Neuronetics Inc Net Assets Breakdown (December 2025)
Neuronetics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $690.00K | 3.08% |
| Other Components | $480.48 Million | 2147.09% |
| Total Equity | $22.38 Million | 100.00% |
Neuronetics Inc Competitors by Market Cap
The table below lists competitors of Neuronetics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shree Digvijay Cement Co.Ltd
NSE:SHREDIGCEM
|
$86.29 Million |
|
Sao Ta Foods JSC
VN:FMC
|
$86.33 Million |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
$86.34 Million |
|
TAT HONG EQ.SRV. DL-08
F:1Q2
|
$86.35 Million |
|
PJBumi Bhd
KLSE:7163
|
$86.26 Million |
|
Empress Royalty Corp
V:EMPR
|
$86.25 Million |
|
Arla Plast AB
ST:ARPL
|
$86.25 Million |
|
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
|
$86.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neuronetics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 27,706,000 to 22,378,000, a change of -5,328,000 (-19.2%).
- Net loss of 38,998,000 reduced equity.
- Share repurchases of 1,731,000 reduced equity.
- New share issuances of 29,013,000 increased equity.
- Other factors increased equity by 6,388,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.00 Million | -174.27% |
| Share Repurchases | $1.73 Million | -7.74% |
| Share Issuances | $29.01 Million | +129.65% |
| Other Changes | $6.39 Million | +28.55% |
| Total Change | $- | -19.23% |
Book Value vs Market Value Analysis
This analysis compares Neuronetics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-15786.45 | $2.26 | x |
| 2017-12-31 | $-17170.41 | $2.26 | x |
| 2018-12-31 | $7.94 | $2.26 | x |
| 2019-12-31 | $2.60 | $2.26 | x |
| 2020-12-31 | $1.35 | $2.26 | x |
| 2021-12-31 | $3.34 | $2.26 | x |
| 2022-12-31 | $2.12 | $2.26 | x |
| 2023-12-31 | $1.19 | $2.26 | x |
| 2024-12-31 | $0.87 | $2.26 | x |
| 2025-12-31 | $0.34 | $2.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neuronetics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -174.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.15%
- • Asset Turnover: 1.05x
- • Equity Multiplier: 6.33x
- Recent ROE (-174.27%) is below the historical average (-72.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -32.82% | 1.38x | 0.00x | $6.48 Million |
| 2017 | 0.00% | -39.72% | 1.04x | 0.00x | $3.21 Million |
| 2018 | -33.92% | -45.66% | 0.45x | 1.65x | $-31.20 Million |
| 2019 | -60.70% | -46.35% | 0.63x | 2.09x | $-33.83 Million |
| 2020 | -107.69% | -55.75% | 0.63x | 3.09x | $-30.00 Million |
| 2021 | -36.62% | -56.39% | 0.39x | 1.66x | $-39.71 Million |
| 2022 | -65.12% | -56.99% | 0.56x | 2.05x | $-42.87 Million |
| 2023 | -88.30% | -42.31% | 0.62x | 3.39x | $-33.61 Million |
| 2024 | -157.76% | -58.36% | 0.53x | 5.09x | $-46.48 Million |
| 2025 | -174.27% | -26.15% | 1.05x | 6.33x | $-41.24 Million |
Industry Comparison
This section compares Neuronetics Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neuronetics Inc (STIM) | $17.06 Million | 0.00% | 6.35x | $86.29 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Neuronetics Inc
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a p… Read more